An observational study in Bile Leak, Biliary Fistula and Postoperative Complications, sponsored by Minia University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Minia University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Postoperative Complications with a site in Egypt — 13 open to participants now, 15 under way, 1 of them phase 3. Postoperative Complications · Egypt.
Among the 44 studies in Postoperative Complications with a site in Egypt, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is one of 9 that started in 2026, is one of 14 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 44th registered.
1,338 studies on the registry are indexed under Postoperative Complications; 311 are open to participants now.
Browse Postoperative Complications studies →13 of the 44 studies in Postoperative Complications with a site in Egypt are open now. Recruiting first, the newest first:
Minia University · Sites in Egypt
Ages 18–75
Minia University · Sites in Egypt
Ages 18+
Minia University · Sites in Egypt
Ages 18–80
Suez Canal University · Sites in Egypt
Ages 20–70
Future University in Egypt · Sites in Egypt
Ages 18–75
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 201 Postoperative Complications studies recruiting now, 126 (63%) set no upper age limit and 32 (16%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 2 · Phase 4 4
First in 2014; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 251 across 539 observational studies indexed under Postoperative Complications.
Median enrollment 90 across the 30 interventional studies, 85 across the 14 observational. Of the 24 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 44 has an industry lead sponsor. The 10 most frequent:
Minia University is the lead sponsor of 374 studies on the registry; 121 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Minia University has 6 studies filed under Postoperative Complications — fewer than ten, so there is no comparison to draw.
8 of the studies in Postoperative Complications with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07884006Assiut UniversityImpact of Nutritional Status Before Joint Replacement on Infection Risk | 2026-12-01 |
| NCT07428057Minia UniversityPostoperative Hypocalcemia After Thyroidectomy | 2026-12-01 |
| NCT07144683Minia UniversityAnastomotic Leakage After Colorectal Surgery. | 2027-03-25 |
| NCT07916246Beni-Suef UniversityIntracuff Dexmedetomidine Versus Alkalinized Lidocaine for Peri-Extubation Cough and Hemodynamic Responses in Elderly Patients | 2027-04 |
| NCT07911956Ain Shams UniversityComparison of Functional Results and Complications Between K-Wire Tension Band Fixation and Interosseous Suturing in Transverse Patellar Fractures: A Randomized Controlled Trial | 2027-04-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 44 studies in Postoperative Complications with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn how often bile leaks after major liver surgery, which factors increase the risk of a leak, and whether simple bilirubin tests on the fluid collected by the surgical drain in the first days after the operation can predict a serious leak. The study will include adults having planned removal of three or more liver segments (major hepatectomy) for any reason at Minia University, Egypt.
The main questions it aims to answer are:
Participants are adults whose liver operation has already been planned as part of their regular medical care. Taking part does not change their operation or treatment. Participants will:
The researchers expect that higher drain-fluid bilirubin and a higher drain-to-blood bilirubin ratio early after surgery will identify patients at risk of a clinically relevant leak. If so, these simple tests could help surgeons decide when a drain can be removed safely and when a patient needs early investigation.
Background
Bile leak is one of the most frequent complications of liver resection and an important cause of morbidity after hepatectomy. In 2011 the International Study Group of Liver Surgery (ISGLS) defined post-hepatectomy bile leak as a bilirubin concentration in the drain fluid at least 3 times the simultaneous serum bilirubin concentration on or after postoperative day (POD) 3, or the need for radiological or operative intervention for biliary collections or bile peritonitis. Severity is graded by its effect on clinical management: grade A causes no change in management, grade B requires active therapeutic intervention without relaparotomy, and grade C requires relaparotomy (Koch et al., 2011).
Prospective ISGLS-graded series show a wide range of incidence. In an international multicenter study of 949 consecutive liver resections, bile leak occurred in 7.3% of patients (grade A 3.3%, grade B 3.4%, grade C 0.6%); severity correlated with the Clavien-Dindo classification, and median hospital stay increased from 7 to 15 days when a leak occurred (Brooke-Smith et al., 2015). In 501 consecutive resections the overall rate was 14.0% (grade B 8.0%, grade C 3.2%), and pre-operative chemotherapy, major hepatectomy and biliodigestive reconstruction were independent risk factors (Spetzler et al., 2019). In 265 elective resections, grade B and grade C leaks occurred in 14.3% and 4.1% of patients, with perioperative mortality of 5.2% and 45.4%, respectively (Rahbari et al., 2012).
Other reported risk factors include central hepatectomy, prolonged operative time and Child-Pugh class B cirrhosis (Nakano et al., 2018), and non-anatomical resection (Panaro et al., 2016; Kajiwara et al., 2016). A 2023 meta-analysis of 39 studies including 43,824 patients identified, among other factors, repeat hepatectomy, extended hepatectomy, diabetes, Child-Pugh class B or worse and chemotherapy as factors associated with grade B/C bile leak (Xue et al., 2023).
Early biochemical detection is attractive because it could allow safe early drain removal in low-risk patients and prompt investigation in those developing a clinically relevant leak. A drain-fluid bilirubin concentration of 2.4 mg/dL or more on POD 2 independently predicted grade B/C leak (odds ratio 11.88, 95% CI 5.33 to 26.49) (Rahbari et al., 2012). After complex hepatectomy, drain-fluid total bilirubin on POD 3 had the highest predictive value for grade B leak (Taguchi et al., 2014), and in 576 resections the drain-to-serum bilirubin ratio discriminated grade B/C leak with areas under the curve of 0.788 on POD 1, 0.791 on POD 2 and 0.650 on POD 3 (Sliwinski et al., 2023).
Rationale
Most published evidence is retrospective, heterogeneous in definitions, case mix and drainage policy, and drawn from mixed minor and major resections. Prospective data that apply the ISGLS definition uniformly to major hepatectomy, and that evaluate pre-operative, intraoperative and early biochemical predictors in the same cohort, remain limited. Drain-fluid bilirubin and the drain-to-serum bilirubin ratio are inexpensive and widely available, and could directly inform drain management and enhanced-recovery pathways. No prospective ISGLS-based analysis of bile leak after major hepatectomy has been reported from this institution.
Objectives
Primary objective: to estimate the incidence of clinically relevant (ISGLS grade B/C) bile leak within 90 days after major hepatectomy.
Secondary objectives:
Hypotheses
Null hypothesis: early drain-fluid bilirubin and the drain-to-serum bilirubin ratio do not discriminate between patients who do and do not develop clinically relevant bile leak, and the candidate pre-operative and intraoperative factors are not associated with bile leak.
Alternative hypothesis: higher early drain-fluid bilirubin and a higher drain-to-serum bilirubin ratio are associated with, and predictive of, clinically relevant bile leak, and defined pre-operative and intraoperative factors are independently associated with its occurrence.
Design and Setting
Single-center, prospective, observational cohort study, conducted and reported in accordance with the STROBE statement (von Elm et al., 2007). The study takes place in the Hepato-Pancreato-Biliary (HPB) Unit, Department of General Surgery, Liver and Gastrointestinal Tract Hospital, Faculty of Medicine, Minia University, Minia, Egypt, and forms the thesis research for the Master of Science degree in General Surgery, Faculty of Medicine, Minia University.
Participants and Enrollment
Consecutive adults scheduled for elective major hepatectomy are screened and, after written informed consent, enrolled at the decision to operate (consecutive, total-population sampling). The eligibility criteria are listed in the Eligibility section of this record. Participants in whom no abdominal drain is placed (unless bile leak is diagnosed by intervention), and those who die within 72 hours of surgery from a cause unrelated to bile leak, are recorded as non-evaluable for the primary outcome and reported in the STROBE flow diagram.
Operational Definitions
Study Procedures
Pre-operative assessment: history and examination, routine hematology and biochemistry (including liver profile, INR and albumin), tumor markers as indicated, and triphasic computed tomography and/or magnetic resonance imaging with volumetric assessment of the future liver remnant when major resection is planned. Liver function is characterized by Child-Pugh class and, where available, indocyanine green retention at 15 minutes (ICG-R15). Baseline variables are recorded prospectively on the case report form.
Operation and drainage: resections are performed by the unit's HPB surgeons according to standard practice (open or minimally invasive), with parenchymal transection and hemostasis by the operator's usual technique. The biliary integrity of the cut surface is assessed according to unit practice, and use of an intraoperative bile-leak test is recorded. In line with the unit's drainage practice after major hepatectomy, a closed-suction abdominal drain is placed adjacent to the transection surface at the end of the procedure, including all cases with biliary reconstruction; the protocol standardizes drain position and the sampling schedule so that bile leak can be assessed uniformly. Operative details are recorded at the time of surgery.
Postoperative sampling and monitoring:
Samples are analyzed in the hospital laboratory and are not stored. Drain removal and all management decisions remain with the treating team; no experimental intervention is imposed.
Outcome ascertainment and follow-up: participants are assessed daily during the index admission and reviewed in the outpatient clinic approximately 2 weeks, 6 weeks and 90 days after surgery, or more often if clinically indicated. Readmissions and interventions within 90 days are captured. Bile leak, post-hepatectomy liver failure and post-hepatectomy hemorrhage are graded according to the ISGLS definitions; the diagnosis and grade of bile leak are assigned prospectively by the managing team and independently verified by the investigators.
Candidate Predictors
Sample Size
The sample size is based on the primary descriptive objective, estimating a single proportion with adequate precision. The expected incidence of clinically relevant bile leak after major hepatectomy is 12%; in prospective ISGLS-graded series of all liver resections, grade B/C leak occurred in 4.0% to 18.4% of patients, and major hepatectomy was an independent risk factor (Brooke-Smith et al., 2015; Spetzler et al., 2019; Rahbari et al., 2012). With 95% confidence (Z = 1.96) and an absolute precision of plus or minus 8%, n = Z² × p(1 - p) / d² = (1.96² × 0.12 × 0.88) / 0.08² = 63.4, rounded up to 64 evaluable patients. Allowing about 10% non-evaluable patients (early unrelated death, absent drain or loss to follow-up), at least 72 patients are required.
To strengthen the risk-factor and diagnostic-accuracy objectives, all consecutive eligible patients presenting during the 18-month recruitment period will be enrolled, with a target of at least 90 evaluable patients (about 100 enrolled). With 90 evaluable patients, the 95% confidence interval for an incidence of 12% has a half-width of about plus or minus 6.7%. At the anticipated incidence, 90 patients yield roughly 10 to 12 grade B/C events, a low number of events per variable (Peduzzi et al., 1996); multivariable modeling is therefore pre-specified as exploratory. Where feasibility permits, recruitment may be extended to accrue additional events, and this record will be updated accordingly.
Statistical Analysis
Analyses will use SPSS or R, with two-sided tests and a significance level of 0.05.
Data Management and Quality Control
Data are recorded prospectively on a standardized case report form, pseudonymized with a study identification number, and entered into a secured, access-controlled electronic database with range and consistency checks at entry. The case report form is piloted and finalized before enrollment begins. Source documents are retained according to institutional policy to permit verification, and only the investigators have access to the data.
Ethical Considerations
The protocol was approved by the Medical Research Ethics Committee (Institutional Review Board), Faculty of Medicine, Minia University (MUFMIRB approval number 2259:11/26, 4 November 2026), which operates according to the Declaration of Helsinki, CIOMS and ICH-GCP guidelines and Egyptian Law No. 214 of 2020. The study is conducted in accordance with the Declaration of Helsinki (2013 revision). Written informed consent is obtained from every participant; participation is voluntary, and refusal does not affect the standard of care. The study observes routine surgical care: the standardized drain position and drain-fluid sampling add minimal incremental risk, and treatment decisions remain with the treating team. Serious adverse events are reported immediately to the committee chair, protocol changes are implemented only after committee approval, an annual report is submitted (the approval is valid for one year and will be renewed), and an end-of-study notification is filed.
Timeline
Ethical approval was granted on 4 November 2026, and the study is registered before enrollment begins. Prospective enrollment runs for 18 months, from 25 November 2026 to 24 May 2028; 90-day follow-up is completed by August 2028, followed by analysis and thesis write-up and submission by October 2028.
Reporting and Dissemination
Results will be reported according to the STROBE statement, presented as an MSc thesis and submitted for publication in a peer-reviewed journal.
Limitations
The single-center design may limit generalizability; the expected number of events constrains multivariable modeling, which is exploratory and hypothesis-generating; routine drainage differs from selective or no-drain policies; and case mix (indication, extent of resection and biliary reconstruction) is heterogeneous.
Consecutive adults scheduled for elective major hepatectomy (resection of 3 or more contiguous Couinaud segments) for malignant or benign liver disease at the Hepato-Pancreato-Biliary Unit, Liver and Gastrointestinal Tract Hospital, Faculty of Medicine, Minia University, Minia, Egypt, during an 18-month recruitment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Consecutive adults (18 years or older) undergoing elective major hepatectomy (resection of 3 or more contiguous Couinaud segments) for any malignant or benign indication at the HPB Unit, Liver and Gastrointestinal Tract Hospital, Minia University. All participants receive standard peri-operative care. A closed-suction drain is placed adjacent to the transection surface at the end of surgery according to unit practice, and drain-fluid total and direct bilirubin, with simultaneous serum bilirubin, are measured on postoperative days 1, 3 and 5 and thereafter while the drain remains. Participants are followed for 90 days. The investigators do not assign or modify treatment.
Procedure: Major hepatectomy · Diagnostic Test: Drain-fluid and serum bilirubin measurement
Elective resection of 3 or more contiguous Couinaud segments (right or left hepatectomy, right or left trisectionectomy, or extended or central major resection), open or minimally invasive, with or without biliary reconstruction, performed by the unit's HPB surgeons according to standard practice and ending with placement of a closed-suction drain adjacent to the transection surface. The operation is clinically indicated and planned before enrollment; the study does not assign or modify it.
Also known as: Major liver resection, Hemihepatectomy, Trisectionectomy
Total and direct (conjugated) bilirubin measured in fluid from the closed-suction abdominal drain on postoperative days 1 and 3, and on day 5 and subsequently while the drain remains, each with a simultaneous serum total bilirubin to calculate the drain-to-serum bilirubin ratio. Fluid is taken from the drain collection without any additional procedure, analyzed in the hospital laboratory and not stored. Drain management remains at the discretion of the treating team.
Also known as: Drain bilirubin, Drain-to-serum bilirubin ratio, Bilirubin ratio
Incidence of Clinically Relevant (ISGLS Grade B or C) Bile Leak
Number and percentage of participants who develop bile leak of International Study Group of Liver Surgery (ISGLS) grade B or C, reported with a 95% confidence interval. Bile leak is defined as a drain-fluid bilirubin concentration at least 3 times the simultaneous serum bilirubin concentration on or after postoperative day 3, or the need for radiological or operative intervention for biliary collection or bile peritonitis. Grade B requires active therapeutic intervention (for example percutaneous drainage or endoscopic retrograde cholangiopancreatography with or without stenting) without relaparotomy; grade C requires relaparotomy. Diagnosis and grade are assigned prospectively by the treating team and independently verified by the investigators against the ISGLS criteria.
Time frame: From surgery to 90 days after surgery
Incidence of Any ISGLS Bile Leak (Grade A, B or C)
Number and percentage of participants who meet the ISGLS definition of bile leak of any grade, reported with a 95% confidence interval. Grade A causes no change in clinical management; grades B and C are defined as for the primary outcome.
Time frame: From surgery to 90 days after surgery
Severity Grade of Bile Leak (ISGLS Grade A, B and C)
Number and percentage of participants with ISGLS grade A, grade B and grade C bile leak, respectively, reported among all evaluable participants and among those with bile leak.
Time frame: From surgery to 90 days after surgery
Time From Surgery to Diagnosis of Bile Leak
Postoperative day on which bile leak is first diagnosed according to the ISGLS definition (first drain-to-serum bilirubin ratio of 3 or more on or after postoperative day 3, or date of the first intervention for biliary collection or bile peritonitis), reported as median and interquartile range among participants with bile leak.
Time frame: From surgery to 90 days after surgery
Pre-operative and Intraoperative Factors Associated With Bile Leak
Odds ratios with 95% confidence intervals for the association of each pre-specified candidate factor with bile leak of any grade and with clinically relevant (grade B/C) bile leak, from univariable analysis and an exploratory Firth penalized multivariable logistic regression model in which the number of covariates is limited by the number of events. Candidate factors: demographic and baseline (age, sex, body mass index, smoking, diabetes, ASA class, albumin, weight loss); hepatic and disease-related (diagnosis, cirrhosis and Child-Pugh class, portal hypertension, pre-operative jaundice, ICG-R15, liver tests, platelet count, future liver remnant volume); pre-operative chemotherapy and biliary drainage; operative (extent and type of resection, biliary reconstruction, hilar dissection or caudate involvement, operative time, blood loss, transfusion, Pringle maneuver and clamp time, cut-surface area, bile-leak test, concomitant procedures).
Time frame: Pre-operative and intraoperative data; bile leak assessed from surgery to 90 days after surgery
Accuracy of Drain-Fluid Total Bilirubin on Postoperative Days 1 and 3 for Predicting Clinically Relevant Bile Leak
Area under the receiver operating characteristic curve (AUC) with 95% confidence interval of the drain-fluid total bilirubin concentration (mg/dL) measured on postoperative day 1 and on postoperative day 3 for predicting ISGLS grade B or C bile leak. For each day, the optimal cut-off (maximum Youden index) is reported with its sensitivity, specificity and positive and negative predictive values. The AUCs on days 1 and 3 are compared by the DeLong method.
Time frame: Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery
Accuracy of Drain-Fluid Direct Bilirubin on Postoperative Days 1 and 3 for Predicting Clinically Relevant Bile Leak
Area under the receiver operating characteristic curve (AUC) with 95% confidence interval of the drain-fluid direct (conjugated) bilirubin concentration (mg/dL) measured on postoperative day 1 and on postoperative day 3 for predicting ISGLS grade B or C bile leak. For each day, the optimal cut-off (maximum Youden index) is reported with its sensitivity, specificity and positive and negative predictive values. The AUCs on days 1 and 3 are compared by the DeLong method.
Time frame: Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery
Accuracy of the Drain-to-Serum Bilirubin Ratio on Postoperative Days 1 and 3 for Predicting Clinically Relevant Bile Leak
Area under the receiver operating characteristic curve (AUC) with 95% confidence interval of the drain-to-serum total bilirubin ratio (drain-fluid total bilirubin divided by simultaneous serum total bilirubin) measured on postoperative day 1 and on postoperative day 3 for predicting ISGLS grade B or C bile leak. For each day, the optimal cut-off (maximum Youden index) is reported with its sensitivity, specificity and positive and negative predictive values. The AUCs on days 1 and 3 are compared by the DeLong method.
Time frame: Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery
Accuracy of Postoperative Day 1 Drain-Fluid Total Bilirubin for Predicting Bile Leak of Any Grade
AUC with 95% confidence interval of the drain-fluid total bilirubin concentration (mg/dL) on postoperative day 1 for predicting ISGLS bile leak of any grade (A, B or C), with the optimal cut-off (maximum Youden index) and its sensitivity, specificity and positive and negative predictive values. Day 3 values are not evaluated against any-grade leak because the ISGLS biochemical criterion is applied from postoperative day 3 (incorporation bias).
Time frame: Measured on postoperative day 1; bile leak assessed to 90 days after surgery
Accuracy of Postoperative Day 1 Drain-Fluid Direct Bilirubin for Predicting Bile Leak of Any Grade
AUC with 95% confidence interval of the drain-fluid direct (conjugated) bilirubin concentration (mg/dL) on postoperative day 1 for predicting ISGLS bile leak of any grade (A, B or C), with the optimal cut-off (maximum Youden index) and its sensitivity, specificity and positive and negative predictive values. Day 3 values are not evaluated against any-grade leak because the ISGLS biochemical criterion is applied from postoperative day 3 (incorporation bias).
Time frame: Measured on postoperative day 1; bile leak assessed to 90 days after surgery
Accuracy of the Postoperative Day 1 Drain-to-Serum Bilirubin Ratio for Predicting Bile Leak of Any Grade
AUC with 95% confidence interval of the drain-to-serum total bilirubin ratio on postoperative day 1 for predicting ISGLS bile leak of any grade (A, B or C), with the optimal cut-off (maximum Youden index) and its sensitivity, specificity and positive and negative predictive values. Day 3 values are not evaluated against any-grade leak because the ISGLS biochemical criterion is applied from postoperative day 3 (incorporation bias).
Time frame: Measured on postoperative day 1; bile leak assessed to 90 days after surgery
Discrimination and Calibration of the Exploratory Multivariable Model for Bile Leak
Apparent discrimination (AUC with 95% confidence interval) and calibration (Hosmer-Lemeshow goodness-of-fit test) of the exploratory Firth penalized logistic regression model of pre-operative and intraoperative factors for bile leak.
Time frame: Bile leak assessed from surgery to 90 days after surgery
Management of Bile Leak
Number and percentage of participants with bile leak managed by each of the following (more than one may apply): observation with the drain kept in place; new or prolonged percutaneous drainage; endoscopic retrograde cholangiopancreatography with or without stenting; antibiotic therapy; and relaparotomy.
Time frame: From diagnosis of bile leak to 90 days after surgery
Time to Resolution of Bile Leak
Days from diagnosis of bile leak to resolution, defined as cessation of bilious drainage with removal of all abdominal drains and no further biliary intervention, as documented by the treating team; reported as median and interquartile range.
Time frame: From diagnosis of bile leak to 90 days after surgery
Incidence and Grade of Post-hepatectomy Liver Failure (ISGLS)
Number and percentage of participants with post-hepatectomy liver failure, defined by the ISGLS as an increased international normalized ratio with concomitant hyperbilirubinemia (local laboratory limits) on or after postoperative day 5, and graded A (no change in clinical management), B (deviation from the regular course without invasive treatment) or C (invasive treatment required); compared between participants with and without bile leak.
Time frame: From postoperative day 5 to 90 days after surgery
Incidence and Grade of Post-hepatectomy Hemorrhage (ISGLS)
Number and percentage of participants with post-hepatectomy hemorrhage, defined by the ISGLS as a fall in hemoglobin of more than 3 g/dL from the postoperative baseline, and/or postoperative red cell transfusion for falling hemoglobin, and/or radiological intervention or relaparotomy to stop bleeding; graded A (transfusion of up to 2 units), B (more than 2 units) or C (invasive reintervention).
Time frame: From surgery to 90 days after surgery
Overall Postoperative Morbidity by Clavien-Dindo Grade
Number and percentage of participants with any complication and with major complications (grade III or higher), classified by the highest Clavien-Dindo grade (I to V); compared between participants with and without bile leak.
Time frame: From surgery to 90 days after surgery
Comprehensive Complication Index (CCI)
Comprehensive Complication Index score (scale 0 to 100; 0 = no complication, 100 = death), calculated from all complications graded by the Clavien-Dindo classification; reported as median and interquartile range and compared between participants with and without bile leak.
Time frame: From surgery to 90 days after surgery
Reintervention
Number and percentage of participants requiring radiological, endoscopic or surgical reintervention for any cause, reported overall and by type.
Time frame: From surgery to 90 days after surgery
Length of Postoperative Hospital Stay
Days from surgery to discharge from the index admission; reported as median and interquartile range and compared between participants with and without bile leak.
Time frame: From surgery to discharge from the index admission (up to 90 days)
Length of Intensive Care Unit Stay
Number of days spent in the intensive care unit during the index admission; reported as median and interquartile range and compared between participants with and without bile leak.
Time frame: From surgery to discharge from the index admission (up to 90 days)
Hospital Readmission
Number and percentage of participants readmitted to hospital for any cause, and for bile leak-related causes, after discharge from the index admission.
Time frame: From discharge to 90 days after surgery
All-Cause Mortality
Number and percentage of participants who die from any cause within 30 days and within 90 days after surgery; compared between participants with and without bile leak.
Time frame: 30 days and 90 days after surgery
Duration of Abdominal Drainage
Days from surgery to removal of the last abdominal drain; reported as median and interquartile range and compared between participants with and without bile leak.
Time frame: From surgery to removal of the last drain (up to 90 days)
Incidence of Bile Leak by Type of Resection and Biliary Reconstruction
Number and percentage of participants with bile leak of any grade and with clinically relevant (grade B or C) bile leak, by extent of resection (right, left, extended or central) and by presence or absence of biliary reconstruction; descriptive only.
Time frame: From surgery to 90 days after surgery
Early Postoperative Variables Associated With Clinically Relevant Bile Leak
Comparison of daily drain output volume (postoperative days 1 to 3), serum bilirubin trajectory (postoperative days 1, 3 and 5), and C-reactive protein and white cell count on postoperative day 3 between participants with and without clinically relevant bile leak, reported as median (IQR) or mean (SD) with univariable P values.
Time frame: Postoperative days 1 to 5; bile leak assessed to 90 days after surgery
Plan to share: No
Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.
Of 277 non-industry observational studies under Postoperative Complications, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 21 months is close to that.
Counting every sponsor, half of 282 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.